Bisphosphonates for Secondary Prevention of Osteoporotic Fractures: A Bayesian Network Meta-Analysis of Randomized Controlled Trials
- PMID: 31828096
- PMCID: PMC6885847
- DOI: 10.1155/2019/2594149
Bisphosphonates for Secondary Prevention of Osteoporotic Fractures: A Bayesian Network Meta-Analysis of Randomized Controlled Trials
Abstract
Purpose: To investigate the comparative efficacies of the five most commonly used bisphosphonates for the secondary prevention of osteoporotic fractures in a Bayesian network meta-analysis.
Methods: Five databases and the reference lists of all acquired articles from inception to July 2017 were searched. A Bayesian random-effects model was employed, and vertebral, hip and nonvertebral nonhip fractures were assessed by odds ratios (ORs) and 95%credible intervals. Furthermore, with respect to each endpoint, rank probabilities for each bisphosphonate were evaluated using the surface under the cumulative ranking curve (SUCRA) value.
Results: Thirteen eligible studies were identified involving 11,822 patients with osteoporotic fractures. Overall in the pairwise meta-analyses, bisphosphonate use significantly reduced the risk of new vertebral, hip, and nonvertebral nonhip fractures, with ORs and 95% confidence intervals of 0.56 (0.49-0.64), 0.69 (0.48-0.98), and 0.82 (0.70-0.97), respectively. In network meta-analyses, significant differences were found between placebo and any one of the five bisphosphonates for new vertebral fractures. The rank probability plot and the SUCRA calculation results suggested that alendronate was the best intervention (14.6%) for secondary prevention of vertebral fractures, followed by zoledronate (15.3%) and etidronate (22.1%). In terms of the incidence of new hip fractures, alendronate was associated with the lowest incidence (18.5%), followed by zoledronate (43.1%) and risedronate (52.5%). However, zoledronate ranked lowest (16.6%) regarding the incidence of new nonvertebral nonhip fractures, followed by risedronate (23.8%) and alendronate (44.1%).
Conclusions: Bisphosphonates show significant efficacy for secondary prevention of new vertebral fractures, and alendronate is most likely to be successful at secondary prevention of vertebral and hip fractures compared with the other four bisphosphonates.
Copyright © 2019 Lei Shi et al.
Conflict of interest statement
The authors declare that they have no conflict of interest.
Figures
Similar articles
-
Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses.Osteoporos Int. 2016 Nov;27(11):3289-3300. doi: 10.1007/s00198-016-3654-z. Epub 2016 Jun 7. Osteoporos Int. 2016. PMID: 27273112 Review.
-
Bisphosphonates in multiple myeloma: an updated network meta-analysis.Cochrane Database Syst Rev. 2017 Dec 18;12(12):CD003188. doi: 10.1002/14651858.CD003188.pub4. Cochrane Database Syst Rev. 2017. PMID: 29253322 Free PMC article. Review.
-
Clinical efficacy and safety of drug interventions for primary and secondary prevention of osteoporotic fractures in postmenopausal women: Network meta-analysis followed by factor and cluster analysis.PLoS One. 2020 Jun 3;15(6):e0234123. doi: 10.1371/journal.pone.0234123. eCollection 2020. PLoS One. 2020. PMID: 32492050 Free PMC article.
-
Denosumab Versus Bisphosphonates for the Prevention of the Vertebral Fractures in Men with Osteoporosis: An Updated Network Meta-Analysis.Clin Invest Med. 2022 Sep 21;45(3):E14-22. doi: 10.25011/cim.v45i3.38875. Clin Invest Med. 2022. PMID: 36149052
-
Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.Osteoporos Int. 2010 Jun;21(6):1021-9. doi: 10.1007/s00198-009-1046-3. Epub 2009 Sep 1. Osteoporos Int. 2010. PMID: 19722103 Free PMC article.
Cited by
-
Recent advances in the identification of related factors and preventive strategies of hip fracture.Front Public Health. 2023 Mar 13;11:1006527. doi: 10.3389/fpubh.2023.1006527. eCollection 2023. Front Public Health. 2023. PMID: 36992874 Free PMC article. Review.
-
Osteoporosis Medications Prevent Subsequent Fracture in Frail Older Adults.J Bone Miner Res. 2022 Nov;37(11):2103-2111. doi: 10.1002/jbmr.4693. Epub 2022 Sep 27. J Bone Miner Res. 2022. PMID: 36168189 Free PMC article.
-
Secondary Prevention of Osteoporosis: If Not Now, When?Rambam Maimonides Med J. 2022 Jul 31;13(3):e0021. doi: 10.5041/RMMJ.10478. Rambam Maimonides Med J. 2022. PMID: 35921486 Free PMC article. No abstract available.
-
Comparison of the Effect of Different Local Analgesia Administration Methods in Percutaneous Vertebroplasty: A Retrospective Cohort Study.Front Surg. 2022 Mar 25;9:769102. doi: 10.3389/fsurg.2022.769102. eCollection 2022. Front Surg. 2022. PMID: 35402496 Free PMC article.
-
Spinal Orthoses Prescription for Vertebral Fragility Fractures by Italian Physical and Rehabilitation Medicine Physicians: The SPIN-VER Survey.Healthcare (Basel). 2021 Jul 15;9(7):892. doi: 10.3390/healthcare9070892. Healthcare (Basel). 2021. PMID: 34356276 Free PMC article.
References
-
- Larijani B., Tehrani M. R. M., Hamidi Z., Soltani A., Pajouhi M. Osteoporosis, prevention, diagnosis and treatment. Journal of Reproduction & Infertility. 2005;6
-
- Cummings S. R., Melton L. J. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002;359:1761–1767. - PubMed
-
- Nazrun A. S., Tzar M. N., Mokhtar S. A., Mohamed I. N. A systematic review of the outcomes of osteoporotic fracture patients after hospital discharge: morbidity, subsequent fractures, and mortality. Therapeutics and Clinical Risk Management. 2014;10:937–948. doi: 10.2147/tcrm.s72456. - DOI - PMC - PubMed
-
- Wang G., Sui L., Gai P., Li G., Qi X., Jiang X. The efficacy and safety of vertebral fracture prevention therapies in post-menopausal osteoporosis treatment: which therapies work best? a network meta-analysis. Bone Joint Research. 2017;6(7):452–463. doi: 10.1302/2046-3758.67.bjr-2016-0292.r1. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
